Immunic sets stage for phase 3 MS data readout after $400M financing

Immunic secured an oversubscribed private placement of up to $400 million (including $200M upfront and ~ $187M net proceeds counted toward cash runway) and advanced oral vidofludimus calcium (IMU-838) into twin phase 3 ENSURE-1/2 trials with top-line readouts expected by year-end 2026, a planned US NDA submission mid-2027 and potential approval in 2028. The financing plus current cash ($15.5M at end-2025) is expected to fund operations into late-2027; the company also plans a phase 3 program for PPMS after supportive phase 2 CALLIPER data, has initiated leadership changes (interim chair Simona Skerjanec, BVF partner Thor Nagel joining the board) and is searching for a commercial-experienced CEO as it prepares for potential commercialization.

Analysis

Market structure: Immunic’s $400M financing and phase 3 readout timeline (ENSURE-1/2 top-lines by end‑2026; NDA mid‑2027) materially derisk near-term equity dilution and funds operations into late‑2027, increasing probability of a commercial transition. If vidofludimus shows superiority on both relapse and progression metrics, expect share re-rating and incremental pricing pressure on oral RMS incumbents (Novartis, NVS; Sanofi, SNY products), but initial uptake will be supply‑constrained by manufacturing/regulatory timelines through 2028. Investors should model a 30–60% market share capture in target oral-switch cohorts over 3–5 years in best‑case; failure yields typical binary downside >60–80% for IMUX. Cross‑asset: expect IMUX equity IV to spike into the readout (elevated options activity), negligible FX/commodity impact, and idiosyncratic biotech credit moves if Immunic issues debt or raises additional capital.

Key Decisions for Investors

• Establish a staged long position in IMUX equal to 2–3% of portfolio equity: deploy 50% now and 50% by Q3 2026 (or upon positive interim signals), with a stop‑loss at −40% from entry and profit targets of +150–300% on a positive ENSURE readout by YE2026.
• Buy long‑dated call LEAPs (Jan 2028 expiry) representing 0.5–1% notional to capture upside into NDA/approval window; prefer debit call spreads to cap cost and limit theta decay, sizing to risk budget and avoiding front‑month binary IV spikes.
• Purchase a protective put spread (Dec 2026 expiry) equal to 0.5% notional as insurance into the ENSURE readout; if implied volatility rises >30% vs 90‑day average, widen strikes or shift to put‑spread to control premium.
• Pair trade for market‑neutral exposure: long IMUX 2% vs short XBI (SPDR S&P Biotech ETF) 1% to hedge broad biotech selloffs while retaining idiosyncratic upside; rebalance after readout or if IMUX moves ±30% pre‑readout.
• Do not add materially beyond these sizes until 1) ENSURE top‑line or positive interim safety signals appear (by YE2026) or 2) management hires a commercial CEO and provides a granular US launch budget (expected pre‑NDA in H1 2027).